ReviewDiabetologia2014
Peptide YY: more than just an appetite regulator.
Review in Diabetologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 91 citations in OpenAlex.
- SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans.Diabetes · 2021Trial
- Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.Diabetes, obesity & metabolism · 2021Trial
- Mechanisms of neuropeptide-mediated immune sensing in the modulation of antitumor immunity.Journal for immunotherapy of cancer · 2026Review
- Nutraceuticals as modulators of genetic, epigenetic and hormonal factors in obesity.European journal of clinical nutrition · 2026Review
- Therapeutic potential of modulating endogenous PYY expression for controlling overweight and obesity: a narrative review.Frontiers in nutrition · 2026Review
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- Peptide YY in Type 2 Diabetes: A Complementary Gut Hormone with Therapeutic Potential Beyond GLP-1.Nutrients · 2025Review
- Distinct molecular patterns in R6/2 HD mouse brain: Insights from spatiotemporal transcriptomics.Neuron · 2025Article
- An adeno-associated virus gene therapy strategy for anti-obesity treatment by nanocarrier-based delivery systems.Journal of nanobiotechnology · 2025Article
- Gestational saccharin consumption disrupts gut-brain axis glucose homeostasis control in adolescent offspring rats in a sex-dependent manner.Biology of sex differences · 2025Article
- The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review.Journal of translational medicine · 2025Review
- Cross-talk between microbiota-gut-brain axis and blood pressure regulation.Clinical science (London, England : 1979) · 2025Review
- Transition to Piscivory Seen Through Brain Transcriptomics in a Juvenile Percid Fish: Complex Interplay of Differential Gene Transcription, Alternative Splicing, and ncRNA Activity.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2025Article
- Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.Signal transduction and targeted therapy · 2025Review
- Neuroprotective Mechanisms and Clinical Evidence for Acupuncture in Parkinson's Disease: A Systematic Review.Parkinson's disease · 2025Review
- Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacology research & perspectives · 2024Review
- Functional engineering of human iPSC-derived parasympathetic neurons enhances responsiveness to gastrointestinal hormones.FEBS open bio · 2024Article
- The intestine as an endocrine organ and the role of gut hormones in metabolic regulation.Nature reviews. Gastroenterology & hepatology · 2023Review
- The postprandial secretion of peptide YYClinical endocrinology · 2023Article
- Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Replenishment of beta cell mass is a key aim of novel therapeutic interventions for diabetes, and the implementation of new strategies will be aided by understanding the mechanisms employed to regulate beta cell mass under normal physiological conditions. We have recently identified a new role for the gut hormone peptide YY (PYY) and the neuropeptide Y (NPY) receptor systems in the control of beta cell survival. PYY is perhaps best known for its role in regulating appetite and body weight, but its production by islet cells, the presence of NPY receptors on islets and the demonstration that Y1 activation causes proliferation of beta cells and protects them from apoptosis, suggest a role for this peptide in modulating beta cell mass. This review introduces PYY and its potential role in glucose homeostasis, then focuses on evidence supporting the concept that PYY and NPY receptors are exciting new targets for the preservation of beta cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.